Literature DB >> 6506020

A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation.

J F Cade, M R Buchanan, B Boneu, P Ockelford, C J Cater, A L Cerskus, J Hirsh.   

Abstract

Bleeding is an important complication of heparin therapy. A number of low molecular weight heparin fractions produce less bleeding than standard heparin for an equivalent antithrombotic effect in experimental animals. Low molecular weight heparin fractions and fragments are produced by a number of different procedures but their relative effects on haemostasis and thrombosis have not been evaluated. We have compared the antithrombotic and haemorrhagic effects of two low molecular weight heparin fragments and of a heparinoid with porcine mucosa heparin and related these in vivo findings to the results of ex vivo tests of blood coagulation and in vitro tests of platelet vivo tests of blood coagulation and in vitro tests of platelet function. Haemorrhage was assessed using a rabbit ear bleeding model. The antithrombotic effects were assessed by measuring inhibition of a tissue thromboplastin-induced jugular vein thrombus and by inhibition of fibrin and platelet accumulation in an arterial-venous shunt. The ex vivo anticoagulant effects were assessed with the thrombin clotting time, activated partial thromboplastin time and anti-Xa assay, and the effect of these glycosaminoglycans on platelet function was assessed by measuring collagen-induced platelet aggregation. For a similar antithrombotic effect, standard heparin produced significantly more bleeding than the other 3 glycosaminoglycans. The antithrombotic effects of all 4 glycosaminoglycans occurred at similar levels of anti-Xa activity but there was no relationship between blood loss and the effects of these glycosaminoglycans on any of the other tests of blood coagulation. Standard heparin had a greater inhibitory effect on collagen-induced platelet aggregation than the low molecular weight glycosaminoglycans, supporting the possibility that the increased bleeding observed with heparin is related in part to its inhibitory effect on platelet function.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6506020     DOI: 10.1016/0049-3848(84)90265-2

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  14 in total

Review 1.  New advances in the management of acute coronary syndromes: 4. Low-molecular-weight heparins.

Authors:  Walter Ageno; Alexander G G Turpie
Journal:  CMAJ       Date:  2002-04-02       Impact factor: 8.262

2.  In situ crosslinkable heparin-containing poly(ethylene glycol) hydrogels for sustained anticoagulant release.

Authors:  Aaron D Baldwin; Karyn G Robinson; Jaimee L Militar; Christopher D Derby; Kristi L Kiick; Robert E Akins
Journal:  J Biomed Mater Res A       Date:  2012-05-21       Impact factor: 4.396

Review 3.  Formulary management of low molecular weight heparins.

Authors:  W E Wade; B C Martin; J A Kotzan; W J Spruill; M A Chisoholm; M Perri
Journal:  Pharmacoeconomics       Date:  2000-01       Impact factor: 4.981

4.  Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin.

Authors:  G F Handeland; U Abildgaard; H A Holm; K E Arnesen
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 5.  Enoxaparin: a review of its use as thromboprophylaxis in acutely ill, nonsurgical patients.

Authors:  M Asif A Siddiqui; Antona J Wagstaff
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  Treatment of Venous Thromboembolism with Low-Molecular-Weight Heparin.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

7.  Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury.

Authors:  J F Eidt; P Allison; S Noble; J Ashton; P Golino; J McNatt; L M Buja; J T Willerson
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

8.  Low molecular weight heparin in prevention of perioperative thrombosis.

Authors:  A Leizorovicz; M C Haugh; F R Chapuis; M M Samama; J P Boissel
Journal:  BMJ       Date:  1992-10-17

Review 9.  Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice.

Authors:  Jawed Fareed; Debra Hoppensteadt; Jeanine Walenga; Omer Iqbal; Qing Ma; Walter Jeske; Taqdees Sheikh
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 10.  Blood coagulation in patients with chronic heart failure: evidence for hypercoagulable state and potential for pharmacological intervention.

Authors:  Ferruccio De Lorenzo; Neelam Saba; Vijay V Kakkar
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.